TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06567964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block(ESPB)
Description: ESPB was administered preoperatively under ultrasound guidance via a high-frequency linear probe (Sonosite M-Turbo, Fujifilm Sonosite Inc., USA) (Figure 1). The procedure was as follows:~1. Patient Positioning: The patient was positioned in the lateral decubitus position, with the side to be blocked uppermost.~2. Ultrasound Setup: A high-frequency linear ultrasound probe was placed in a parasagittal orientation over the transverse process of the lumbar vertebra at the level of surgery.~3. Needle Insertion: After skin disinfection with chlorhexidine, a 22-gauge, 100-mm needle (Stimuplex A, B. Braun Melsungen AG, Germany) was inserted in-plane to the ultrasound probe. The needle was advanced until the tip contacted the transverse process.~4. Injection: Following negative aspiration to ensure no vascular puncture, 20 mL of 0.5% bupivacaine was injected incrementally, with real-time ultrasound visualization to confirm the correct spread of the anesthetic solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Wound infiltration was performed by the surgeon at the end of the surgery via the following procedure:~1. Preparation: After hemostasis was achieved and before skin closure, 20 mL of 0.5% bupivacaine was prepared in a sterile syringe.~2. For infiltration, the anesthetic mixture was infiltrated into multiple layers of the surgical wound. This included the subcutaneous tissue and muscle layers, ensuring the even distribution of the anesthetic solution to cover the entire surgical area.
Study: NCT05636501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treat-to-target Prednisolone Taper
Description: Systematic prednisolone taper

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Prednisolone taper performed by discretion of the patient's general practitioner.
Study: NCT04831021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis without physical exercise
Description: Hemodialysis control condition

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis with pre-dialytic physical exercise
Description: Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis with per-dialytic physical exercise
Description: Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
Study: NCT06114381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Physical Exercise
Description: Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplements
Description: Vitamin D3 supplement (400mg) once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplements
Description: Vitamin D3 supplement (400mg) once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 Supplements
Description: Vitamin D3 supplement (400mg) once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Management
Description: Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Exposure
Description: Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Exposure
Description: Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Exposure
Description: Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
Study: NCT05339373

Intervention type: DRUG
Group type: OTHER
Intervention: Aceclofenac film-coated tablet 100 mg
Description: Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.

Intervention type: DRUG
Group type: OTHER
Intervention: Aceclofenac film-coated tablet 100 mg
Description: Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.

Intervention type: DRUG
Group type: OTHER
Intervention: Airtal® film-coated tablet 100 mg
Description: Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac.

Intervention type: DRUG
Group type: OTHER
Intervention: Airtal® film-coated tablet 100 mg
Description: Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac.
Study: NCT06139575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 JH020002 Injection
Description: Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
Study: NCT05739422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuropilates online exercise class
Description: Online, remotely supervised neuropilates exercise class

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Online generalised exercise class
Description: Online, remotely supervised generalised exercise class

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised home exercise programme
Description: Unsupervised, home based generalised exercise programme
Study: NCT05451134

Intervention type: OTHER
Intervention: Catecholamines
Description: Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma

Intervention type: OTHER
Intervention: Catecholamines
Description: Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma
Study: NCT04135677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
Study: NCT05300815

Intervention type: OTHER
Intervention: Delphi Questionaire
Description: This study involves the use of questionnaires across 3 rounds as follows:~The objectives of round 1 are to collect participant demographic information and generate a list of adverse events. Round 1 will be open for 3 weeks with email reminders being provided at weeks 1 and 2.~The objectives of round 2 will be to share a list of adverse events generated from round 1 (with the addition of adverse events identified in literature if not generated in round 1) and allow participants to rate from 1-4 how important each item is for inclusion on informed consent. As per round 1, the round 2 questionnaire will remain active for 3 weeks with email reminders sent at weeks 1 and 2.~The objective of round 3 is to further gain consensus on adverse events from the results of round 2 where agreement was not reached. Round 3 remains active for 3 weeks with email reminders sent at weeks 1 and 2.
Study: NCT05750381

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micrococcus luteus Blis Q24 balm
Description: Balm formulation containing probiotic bacteria Micrococcus luteus Q24 for topical applications.
Study: NCT06055205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAC-plan
Description: The participants will be asked to complete electronic questionnaires at baseline, and at 6 weeks and 52 weeks after discharge from the hospital. The completion of these questionnaires will take place during the 6-week follow-up appointment at the hospital (a standard follow-up for all patients undergoing surgery at the Division of Orthopedic Surgery, Oslo University Hospital, Norway). Additionally, participants will be invited for a phone-based follow-up appointment with the study coordinator 52 weeks after discharge. The participants will receive the questionnaires electronically via SMS or email. If electronic options are not feasible, data can be collected through paper questionnaires sent by mail. Data will not be directly obtained from general practitioners.
Study: NCT05797181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical nutrition therapy in kidney diseases
Description: Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates
Study: NCT05949346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Narrative Therapy (MFNT)
Description: MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School services for families of children with Dyslexia
Description: Selected school personnel will deliver services as usual for the control group.
Study: NCT04620746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin Major Determinant (PrePen) Skin Testing
Description: Skin testing followed by oral challenge with amoxicillin 250 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Oral challenge
Description: Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Oral challenge
Description: Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
Study: NCT05237167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder reduction
Description: This is standard of care and only measure as a time component outcome in the study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder reduction
Description: This is standard of care and only measure as a time component outcome in the study
Study: NCT05059873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone 40mg/day for five consecutive days
Study: NCT05750381

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo balm
Description: Placebo balm formulation for topical applications.
Study: NCT05031624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: Single subcutaneous dose of one of four dosages of CDX-0159

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single subcutaneous dose of normal saline
Study: NCT05774600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSW Works
Description: SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Information Control
Description: Provision of online materials for skin cancer prevention.
Study: NCT05600608

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Stimulant Drink
Description: please see description of the drink in the arm/ group section

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Stimulant Drink
Description: please see description of the drink in the arm/ group section
Study: NCT05631067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote blood pressure monitoring
Description: Participants will receive a blood pressure monitor to check daily BPs for two weeks post partum

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NT proBNP assessment
Description: Participants will have biomarker assessment at 0-2 days postpartum

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NT proBNP assessment
Description: Participants will have biomarker assessment at 0-2 days postpartum
Study: NCT05059873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo of 40mg/day for five consecutive days
Study: NCT04740801

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation procedure
Description: Catheter ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav StablePoint ablation catheter
Study: NCT05064397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab will be administered per schedule specified in the arm description.
Study: NCT06162598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventriloquist Puppet
Description: one day preparation intervention applied by researcher for children under the inhaler treatment. Preparation will be 30 minutes long
Study: NCT04526288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo alloHCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT04801030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YourCoViDVaxFacts
Description: The intervention will be delivered via multiple strategies- social media (YouTube, Facebook), radio, newspaper, tv ads, community partner networks. Participants receive culturally-tailored message on COVID-19 and the vaccine. The strategies will have a link that will open to a website that is optimized for viewing on a computer or mobile phone which has the look and feel of an app, but without requiring the user to download anything to the phone. On the website, participants will be prompted to select their top concerns from a list. Based on the responses, the top barriers or need will each be mapped to a corresponding educational message, which will be displayed to the user with appropriate images or graphics.
Study: NCT05126238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
Study: NCT04820725

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plantar pressure and gait
Description: Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plantar pressure and gait
Description: Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
Study: NCT05126238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
Study: NCT05982743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota fermented milk
Description: Participants will take one bottle (65 ml) of Yakult® drink daily, containing at least 6.5 x 10\^9 CFU of Lactobacillus casei strain Shirota, for a period of 4 weeks. Subsequently, there will be a two-week follow-up period.
Study: NCT06227000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Longer and Stronger with SCI
Description: Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
Study: NCT05922722

Intervention type: OTHER
Intervention: Decision-making tool
Description: The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire to assess participant's understanding of the decision-making tool
Study: NCT05021393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Intervention
Description: Medication review, patient education, counseling, and corresponding written recommendation will be performed by clinical pharmacists for all randomized patients.
Study: NCT05673980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This group will not do any intervention
Study: NCT05708248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: 400 mg pentoxifylline tablets twice daily with meals for 6 months
Study: NCT05989061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK customized healing abutment
Description: Guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery
Study: NCT05923944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eco-Rescue
Description: Ecorescue is a gamified adaptation of the multiple object tracking task (MOT) combined with a detection task. It requires to track the spatial position of specific moving targets among visually similar moving distractors, while at the same time detecting briefly flashed events. It was designed to load on attentional control and visuo-spatial working memory. Additionally, targets may express various facial emotions (happy, angry or neutral) requiring some emotional control in addition to attentional control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bejelewed 3
Description: Bejeweled 3 is a commercially available puzzle video game developed and edited by PopCap Games. The main objective is to swap two adjacent gems of seven colors to create a line or row of 3 or more gems of the same type. When these gems are aligned, they disappear, and points are earned. The goal is to get as many points as possible until it is impossible to line up gems. Bejeweled 3 offers a variety of game modes that players can freely explore at their own pace, enhancing the overall enjoyment and providing increased variability during each gaming session. These game modes typically have shorter durations, with a single game usually lasting less than 5 minutes. Bejeweled 3 was chosen as it requires fewer attentional resources compared to Eco-Rescue and because it was reported to reduce stress and anxiety in adult samples (Russoniello et al. 2009, 2013).
Study: NCT05989061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium customized healing abutment
Description: Guided delayed implant and a customized Titanium healing abutment placed simultaneously with implant surgery
Study: NCT05863663

Intervention type: OTHER
Intervention: questionnaire
Description: cross sectional questionnaire
Study: NCT05159947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPT-07A injection
Description: 20mg (2), dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 Injection simulants, dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
Study: NCT04323163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 3 sessions per week, 60 minutes per session for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: 3 sessions per week, 60 minutes per session for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 3 sessions per week, 60 minutes per session for 6 months